SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV-ZEBOV EBOLA VACCINE - Sofia ref.: 116068

Deliverables

Documents, reports (5)

Distribution of month 36 samples from phase I/II clinical trials in Switzerland and Gabon

Migration

Distribution of month 24 samples from phase I/II clinical trials in Switzerland and Gabon

Migration

Distribution of month 48 samples from phase I/II clinical trials in Switzerland and Gabon

Migration

Distribution of samples (serum, plasma, Paxgene tubes) to partners involved in immunogenicity / transcriptomic studies

Migration

Distribution of month 60 samples from phase I/II clinical trials in Switzerland and Gabon

Migration

Publications

Peer reviewed articles (8)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study

Author(s): Vianello E., Gonzalez-Dias P, van Veen S, Engele CG, Quinten E, Monath TP, Medaglini D, VSV-EBOVAC and VSV-EBOPLUS Consortia, Santoro F, Huttner A, Dubey S, Eichberg M, Ndungu FM, Kremsner PG, Essone PN, Agnandji ST, Siegrist CA, Nakaya HI, Ottenhoff THM, and Haks MC
Published in: The Lancet Microbe, 2021, ISSN 1473-3099
Publisher: The Lancet Publishing Group
DOI: 10.1016/s2666-5247(21)00235-4

Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine

Author(s): Francesco Santoro, Alessia Donato, Simone Lucchesi, Sara Sorgi, Alice Gerlini, Marielle Haks, Tom Ottenhoff, Patricia Gonzalez-Dias, VSV-EBOVAC Consortium, VSV-EBOPLUS Consortium, Helder Nakaya, Angela Huttner, Claire-Anne Siegrist, Donata Medaglini, Gianni Pozzi
Published in: Vaccines, 9/2, 2021, Page(s) 67, ISSN 2076-393X
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines9020067

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

Author(s): Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, José F Fernandes, Emmanuel Bache Bache, Lumeka Kabwende, Francis Maina Ndungu, Jessica Brosnahan, Thomas P Monath, Barbara Lemaître, Stéphane Grillet, Miriam Botto, Olivier Engler, Jasmine Portmann, Denise Siegrist, Philip Bejon, Peter Silvera, Peter Kremsner, Claire-Anne Siegrist, Sanjeev KRISHNA, Marylyn M. ADDO, Stephan BECKER,
Published in: The Lancet Infectious Diseases, 18/7, 2018, Page(s) 738-748, ISSN 1473-3099
Publisher: The Lancet Publishing Group
DOI: 10.1016/S1473-3099(18)30165-8

Correlates of vaccine-induced protective immunity against Ebola virus disease

Author(s): Donata Medaglini, Francesco Santoro, Claire-Anne Siegrist
Published in: Seminars in Immunology, 2018, ISSN 1044-5323
Publisher: Academic Press
DOI: 10.1016/j.smim.2018.07.003

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Author(s): Angela Huttner, Claire-Anne Siegrist
Published in: Expert Review of Vaccines, 17/12, 2018, Page(s) 1105-1110, ISSN 1476-0584
Publisher: Future Drugs Ltd.
DOI: 10.1080/14760584.2018.1546582

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination

Author(s): David Pejoski, Casimir de Rham, Paola Martinez-Murillo, Francesco Santoro, Floriane Auderset, Donata Medaglini, Gianni Pozzi, Maria Vono, Paul-Henri Lambert, Angela Huttner, Mariëlle C. Haks, Tom H. M. Ottenhoff, Jean Villard, Claire-Anne Siegrist
Published in: npj Vaccines, 5/1, 2020, ISSN 2059-0105
Publisher: Springer Nature
DOI: 10.1038/s41541-020-0179-4

Safety, immunogenicity and risk–benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions

Author(s): Bache Emmanuel Bache, Martin P Grobusch, Selidji Todagbe Agnandji
Published in: Future Microbiology, 15/2, 2020, Page(s) 85-106, ISSN 1746-0913
Publisher: Future Medicine Ltd.
DOI: 10.2217/fmb-2019-0237

Methods for predicting vaccine immunogenicity and reactogenicity

Author(s): Patrícia Gonzalez-Dias, Eva K. Lee, Sara Sorgi, Diógenes S. de Lima, Alysson H. Urbanski, Eduardo Lv Silveira, Helder I. Nakaya
Published in: Human Vaccines & Immunotherapeutics, 16/2, 2020, Page(s) 269-276, ISSN 2164-5515
Publisher: Landes Bioscience
DOI: 10.1080/21645515.2019.1697110